192 related items for PubMed ID: 32659761
1. Outcome of Newborn Screening for Congenital Adrenal Hyperplasia at Two Time Points.
Eshragh N, Doan LV, Connelly KJ, Denniston S, Willis S, LaFranchi SH.
Horm Res Paediatr; 2020; 93(2):128-136. PubMed ID: 32659761
[Abstract] [Full Text] [Related]
2. Neonatal screening for congenital adrenal hyperplasia in Southern Brazil: a population based study with 108,409 infants.
Kopacek C, de Castro SM, Prado MJ, da Silva CM, Beltrão LA, Spritzer PM.
BMC Pediatr; 2017 Jan 17; 17(1):22. PubMed ID: 28095810
[Abstract] [Full Text] [Related]
3. High frequency of non-classical congenital adrenal hyperplasia form among children with persistently elevated levels of 17-hydroxyprogesterone after newborn screening.
Castro PS, Rassi TO, Araujo RF, Pezzuti IL, Rodrigues AS, Bachega TASS, Silva IN.
J Pediatr Endocrinol Metab; 2019 May 27; 32(5):499-504. PubMed ID: 31028712
[Abstract] [Full Text] [Related]
4. Improved precision of newborn screening for congenital adrenal hyperplasia using weight-adjusted criteria for 17-hydroxyprogesterone levels.
Allen DB, Hoffman GL, Fitzpatrick P, Laessig R, Maby S, Slyper A.
J Pediatr; 1997 Jan 27; 130(1):128-33. PubMed ID: 9003862
[Abstract] [Full Text] [Related]
5. Neonatal screening for congenital adrenal hyperplasia: 17-hydroxyprogesterone levels and CYP21 genotypes in preterm infants.
Nordenström A, Wedell A, Hagenfeldt L, Marcus C, Larsson A.
Pediatrics; 2001 Oct 27; 108(4):E68. PubMed ID: 11581476
[Abstract] [Full Text] [Related]
6. Transient hyper-17-hydroxyprogesteronemia: a clinical subgroup of patients diagnosed at neonatal screening for congenital adrenal hyperplasia.
Cavarzere P, Samara-Boustani D, Flechtner I, Dechaux M, Elie C, Tardy V, Morel Y, Polak M.
Eur J Endocrinol; 2009 Aug 27; 161(2):285-92. PubMed ID: 19451212
[Abstract] [Full Text] [Related]
7. Cortisol in dried blood screening specimens from newborns with raised 17-hydroxyprogesterone and congenital adrenal hyperplasia.
Mitchell ML, Hermos RJ.
Clin Endocrinol (Oxf); 1998 Jun 27; 48(6):757-60. PubMed ID: 9713565
[Abstract] [Full Text] [Related]
8. Utility of a precursor-to-product ratio in the evaluation of presumptive positives in newborn screening of congenital adrenal hyperplasia.
Tieh PY, Yee JK, Hicks RA, Mao CS, Lee WN.
J Perinatol; 2017 Mar 27; 37(3):283-287. PubMed ID: 27929529
[Abstract] [Full Text] [Related]
9. The influence of seasonality and manufacturer kit lot changes on 17α-hydroxyprogesterone measurements and referral rates of congenital adrenal hyperplasia in newborns.
Pearce M, Dauerer E, DiRienzo AG, Caggana M, Tavakoli NP.
Eur J Pediatr; 2017 Jan 27; 176(1):121-129. PubMed ID: 27900477
[Abstract] [Full Text] [Related]
10. Results of screening 1.9 million Texas newborns for 21-hydroxylase-deficient congenital adrenal hyperplasia.
Therrell BL, Berenbaum SA, Manter-Kapanke V, Simmank J, Korman K, Prentice L, Gonzalez J, Gunn S.
Pediatrics; 1998 Apr 27; 101(4 Pt 1):583-90. PubMed ID: 9521938
[Abstract] [Full Text] [Related]
11. A pilot study on newborn screening for congenital adrenal hyperplasia in Beijing.
Gong LF, Gao X, Yang N, Zhao JQ, Yang HH, Kong YY.
J Pediatr Endocrinol Metab; 2019 Mar 26; 32(3):253-258. PubMed ID: 30817302
[Abstract] [Full Text] [Related]
12. Steroid profiling for congenital adrenal hyperplasia by tandem mass spectrometry as a second-tier test reduces follow-up burdens in a tertiary care hospital: a retrospective and prospective evaluation.
Seo JY, Park HD, Kim JW, Oh HJ, Yang JS, Chang YS, Park WS, Lee SY.
J Perinat Med; 2014 Jan 26; 42(1):121-7. PubMed ID: 23989111
[Abstract] [Full Text] [Related]
13. No evidence of an increase in early infant mortality from congenital adrenal hyperplasia in the absence of screening.
Hird BE, Tetlow L, Tobi S, Patel L, Clayton PE.
Arch Dis Child; 2014 Feb 26; 99(2):158-64. PubMed ID: 24225272
[Abstract] [Full Text] [Related]
14. [Neonatal screening for congenital adrenal hyperplasia in Shanghai areas].
Gu X, Zhou J, Ye J.
Zhonghua Yu Fang Yi Xue Za Zhi; 2002 Jan 26; 36(1):16-8. PubMed ID: 11955341
[Abstract] [Full Text] [Related]
15. Newborn screening for congenital adrenal hyperplasia: additional steroid profile using liquid chromatography-tandem mass spectrometry.
Janzen N, Peter M, Sander S, Steuerwald U, Terhardt M, Holtkamp U, Sander J.
J Clin Endocrinol Metab; 2007 Jul 26; 92(7):2581-9. PubMed ID: 17456574
[Abstract] [Full Text] [Related]
16. Congenital adrenal hyperplasia cases identified by newborn screening in one- and two-screen states.
Held PK, Shapira SK, Hinton CF, Jones E, Hannon WH, Ojodu J.
Mol Genet Metab; 2015 Nov 26; 116(3):133-8. PubMed ID: 26296712
[Abstract] [Full Text] [Related]
17. Neonatal screening for congenital adrenal hyperplasia in Taiwan: a pilot study.
Chu SY, Tsai WY, Chen LH, Wei ML, Chien YH, Hwu WL.
J Formos Med Assoc; 2002 Oct 26; 101(10):691-4. PubMed ID: 12517042
[Abstract] [Full Text] [Related]
18. Neonatal Screening for Congenital Adrenal Hyperplasia in Turkey: A Pilot Study with 38,935 Infants.
Güran T, Tezel B, Gürbüz F, Selver Eklioğlu B, Hatipoğlu N, Kara C, Şimşek E, Çizmecioğlu FM, Ozon A, Baş F, Aydın M, Darendeliler F.
J Clin Res Pediatr Endocrinol; 2019 Feb 20; 11(1):13-23. PubMed ID: 30111524
[Abstract] [Full Text] [Related]
19. Newborn screening for congenital adrenal hyperplasia has reduced sensitivity in girls.
Varness TS, Allen DB, Hoffman GL.
J Pediatr; 2005 Oct 20; 147(4):493-8. PubMed ID: 16227036
[Abstract] [Full Text] [Related]
20. Generation of monoclonal antibodies against 17α-hydroxyprogesterone for newborn screening of congenital adrenal hyperplasia.
Morejón García G, García de la Rosa I, González Reyes EC, Rubio Torres A, Quintana Guerra JM, Hernández Marín M, Pérez Mora PL, Feal Carballo S, Lafita Delfino Y, Pupo Infante M, Castells Martínez EM, Rosabal Poloshkov A, Hernández Pérez L.
Clin Chim Acta; 2018 Oct 20; 485():311-315. PubMed ID: 30006291
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
